drugset / Trial / NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

NCT06508099

Phase 2 Recruiting 220 enrolled St. Petersburg State Pavlov Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The therapy under investigation is the addition of 300 000 IU of vitamin A and 100 000 IU of vitamin D before conditioning. The study will include patients with malignant diseases in hematologic response with indications for allogeneic transplantation with matched related or matched unrelated donor.

Timeline

Start
2024-05-15
Primary completion
2026-05
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholecalciferol Other / unclassified 100000 iu Oral
Subject Vitamin A Unknown 300000 iu Oral